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well as further overall survival follow-up, would have 
substantially changed the results. Such modelling would 
inform our acceptance of these data as well as the design 
of any future trials.
Whether the data from IMELDA are deemed practice 
changing or hypothesis generating, IMELDA has 
reopened important debates about the use bevacizumab 
and maintenance chemotherapy that will potentially 
change the treatment of metastatic breast cancer.
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Surgery or topical therapy for vulval intraepithelial neoplasia
The incidence of intraepithelial neoplasia of the vulva 
has been rising for the past few decades,1 possibly 
due to an increase of human papillomavirus (HPV)-
associated high-grade squamous intraepithelial 
lesions, particularly in young women. High-grade 
squamous intraepithelial lesions (vulval intraepithelial 
neoplasia grade 2–3) are typically multifocal and judged 
to cause more than 90% of all diagnosed cases of vulval 
intraepithelial neoplasia. By contrast with low-grade 
squamous intraepithelial lesions (vulval intraepithelial 
neoplasia grade 1–2), which are usually self-limiting 
with a high rate of spontaneous regression, high-
grade squamous intraepithelial lesions can progress 
to invasive carcinoma and are, therefore, deﬁ ned as 
precancerous lesions. Untreated patients have a 6–9% 
risk of progression to vulval carcinoma.2,3
Diﬀ erentiated disease is another type of high-grade 
vulval intraepithelial neoplasia: it is less frequently 
diagnosed than high-grade squamous intraepithelial 
lesions (diagnosed in 2–10% of cases), lesions are usually 
HPV-negative, and the disease is typically associated 
with vulval lichen sclerosus.4 Although HPV-negative 
lesions are widely accepted to have greater potential 
to progress to invasive disease than other lesion types 
(up to 30% higher),3 no predictive markers are known 
for the progressive potential of diﬀ erent types of vulval 
intraepithelial neoplasia. 
Standard treatment for high-grade squamous 
intraepithelial lesions is surgery, either cold-knife 
resection or laser vaporisation, which can result in 
substantial morbidity and potential psychosexual 
dysfunction.5 The main argument for cold-knife 
resection over the otherwise less invasive surgical 
technique of laser vaporisation is possible histological 
detection of occult vulvar carcinoma within a 
preinvasive lesion. However, in a systematic review, 
occult invasive disease was noted in 3% of patients, 
who had mostly microinvasive cancers.2 This relatively 
low risk shifts the focus of management of high-grade 
squamous intraepithelial lesions away from detection 
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of invasive cancer and towards symptom control and 
prevention of carcinogenesis. 
20–30% of patients who undergo a surgical 
intervention have recurrence of disease, irrespective 
of the treatment modality,6 and neither cold-knife nor 
laser surgery can treat eﬀ ectively the underlying cause 
of most high-grade squamous intraepithelial lesions—
HPV infection.7 Topical treatment with the immune-
modiﬁ er imiquimod is an eﬀ ective alternative to 
surgery, with a durable complete response reported in 
35% of patients and a partial response in 38%.8 Side-
eﬀ ects of imiquimod are pain and discomfort in the 
treatment area, fatigue, and headache. Therefore, 
alternative topical regimens with favourable toxic-eﬀ ect 
proﬁ les are needed.
In The Lancet Oncology, Amanda Tristram and 
colleagues present ﬁ ndings of a randomised phase 2 
trial of topical imiquimod and the nucleotide analogue 
cidofovir for treatment of vulval intraepithelial 
neoplasia grade 3.9 Good responses were recorded 
with both drugs, with complete responses noted in 
41 (46%) of 89 patients allocated cidofovir and in 
42 (46%) of 91 patients assigned imiquimod. Distinct 
toxic-eﬀ ect proﬁ les generally seemed to favour 
cidofovir. Toxic eﬀ ects of grade 3 or higher were noted 
in 39 (46%) of 84 patients treated with imiquimod 
and in 31 (37%) of 84 patients treated with cidofovir. 
However, the study was not powered to compare 
eﬃ  cacy or toxic eﬀ ects of the two treatment regimens, 
and comparisons are exploratory. The authors also 
analysed potential predictive markers, but none of 
them, including HPV, was associated with treat-
ment response. HPV-negative lesions—albeit only 
in 12 of 15 patients—showed a better response to 
topical treat ment than did HPV-positive lesions. Unfor-
tunately, Tristram and colleagues did not establish 
pathologically whether HPV-negative lesions were 
diﬀ erentiated vulval intraepithelial neoplasia. 
Currently, no topical drug is approved for treatment of 
vulval intraepithelial neoplasia. Tristram and colleagues’ 
ﬁ ndings9 not only support use of imiquimod in women 
with vulval high-grade squamous intraepithelial lesions 
but also add cidofovir as a potential therapeutic option. 
Implementation of cidofovir in clinical practice will 
be indicated mainly by the durability of treatment 
response, which probably depends on HPV clearance. 
The therapeutic eﬀ ect of cidofovir seems to be both 
antiviral and cytotoxic, which could potentially 
beneﬁ t immunocompromised patients; a reasonable 
response to cidofovir has been reported in HIV-positive 
patients with anal and vulvar high-grade squamous 
intraepithelial lesions.10 The primary endpoint of 
Tristram and colleagues’ study was a complete response 
6 weeks after treatment; since further follow-up is still 
ongoing, the long-term eﬃ  cacy of cidofovir remains to 
be proven.
In the future, topical treatments could evolve to 
become the treatment of choice for people with high-
grade squamous intraepithelial lesions, with cold-
knife resection and laser vaporisation reserved for 
patients not responding to initial treatment. Until 
results of phase 3 studies comparing these different 
treatment modalities are available, the choice of 
treatment will mainly be based on the individual 
patient’s preference.
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